16 Most Promising Stocks According to Wall Street Analysts

Page 11 of 15

5. Merus (NASDAQ:MRUS)

Number of Hedge Fund Holders: 53

Average Upside Potential as of July 7: 72.97%

Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May 30 to June 3, featured presentations on two highly anticipated trials for head and neck squamous cell carcinoma/HNSCC. The announcements for these presentations were made earlier in May.

Merus presented data from its Phase II study of petosemtamab, which is a bispecific monoclonal antibody targeting epidermal growth factor receptor/EGFR and Leucine-rich repeat containing G-Protein coupled receptor 5/LGR5, in combination with Merck’s Keytruda (pembrolizumab) for PDL1+ first-line (1L) HNSCC.

Bicara presented Phase I/Ib data for its ficerafusp alfa, a bispecific fusion protein targeting EGFR and transforming growth factor beta (TGF-β), also in combination with Keytruda in the same patient population. Both Merus and Bicara are progressing their assets into Phase III clinical development. However, Bicara’s ficerafusp alfa is being advanced with a narrower patient population, specifically excluding those positive for human papillomavirus/HPV.

Merus (NASDAQ:MRUS) is a clinical-stage immuno-oncology company that develops antibody therapeutics in the Netherlands.

Page 11 of 15